摘要
目的探讨甲磺酸阿帕替尼治疗晚期肺腺癌的近期疗效及安全性。方法将98例肺腺癌患者按治疗方法不同分为PC组(46例,培美曲塞二钠与顺铂联合化疗)和联合组(52例,甲磺酸阿帕替尼联合培美曲塞二钠+顺铂化疗)。对比两组患者临床疗效及生活质量,同时对比两组患者血清癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原19-9(CA19-9)水平及不良反应发生情况。结果联合组患者客观缓解率(ORR)、疾病控制率(DCR)均高于PC组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CEA、CA125、CA19-9水平均降低,且联合组患者CEA、CA125、CA19-9水平均低于PC组,差异均有统计学意义(P﹤0.05)。联合组患者蛋白尿、高血压发生率均高于PC组,头晕发生率低于PC组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者社会功能、心理功能、躯体功能、物质生活评分均升高,且联合组患者社会功能、心理功能、躯体功能、物质生活评分均高于PC组,差异均有统计学意义(P﹤0.05)。结论甲磺酸阿帕替尼联合培美曲塞二钠+顺铂化疗治疗晚期肺腺癌患者有较好的近期疗效,可提高患者生活质量,降低血清中CEA、CA125、CA19-9水平,且不良反应可耐受。
Objective To investigate the short-term efficacy and safety of apatinib mesylate in the treatment of advanced lung adenocarcinoma.Method A total of 98 patients with lung adenocarcinoma were divided into the PC group(46 cases,pemetrexed disodium combined with cisplatin chemotherapy)and the combination group(52 cases,apatinib mesylate combined with pemetrexed disodium+cisplatin chemotherapy)according to different treatment methods.The clinical efficacy and quality of life of the two groups were compared,and the serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 19-9(CA19-9)levels and the occurrence of adverse reactions were also compared between the two groups.Result The objective response rate(ORR)and disease control rate(DCR)of the combined group were higher than those of the PC group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CEA,CA125,and CA19-9 in the two groups were decreased,and the levels of CEA,CA125,and CA19-9 in the combined group were lower than those in the PC group,and the differences were statistically significant(P<0.05).The incidences of proteinuria and hypertension in the combined group were higher than those in the PC group,the incidence of dizziness was lower than that in the PC group,and the differences were statistically significant(P<0.05).After the treatment,the scores of social function,psychological function,physical function,and material life of the two groups were increased,and the scores of social function,psychological function,physical function,and material life of the patients in the combined group were higher than those in the PC group,and the differences were statistically significant(P<0.05).Conclusion Apatinib mesylate combined with pemetrexed disodium+cisplatin chemotherapy has good short-term efficacy in the treatment of patients with advanced lung adenocarcinoma,which could improve patients’quality of life,reduce the serum levels of CEA,CA125,and CA19-9 whose adverse events could be tolerated.
作者
左彩莹
徐继业
赵妙妙
ZUO Caiying;XU Jiye;ZHAO Miaomao(Department of Oncology,Zhoukou Central Hospital,Zhoukou 466000,He’nan,China)
出处
《癌症进展》
2022年第7期680-683,共4页
Oncology Progress
关键词
甲磺酸阿帕替尼
肺腺癌
晚期
化疗
近期疗效
安全性
apatinib mesylate
lung adenocarcinoma
advanced stage
chemotherapy
short-term efficacy
safety
